It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical information request
Medical information request

LONGTERMS

The LONGTERMS study evaluated the safety and efficacy of fingolimod in patients with relapsing MS with up to 14 years of exposure. This Phase 3b, open-label extension study included patients aged ⩾18 years with a confirmed RMS diagnosis who completed previous Phase 2/3/3b core/extension studies of fingolimod

AEs profile of fingolimod over 10 years: LONGTERMS study1

Longterms table-v
Link to article DoI
border
Abbreviations
AE, adverse event; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; IR, incidence rate; SAE, serious AE; N, Number of active patients (i.e., did not discontinue permanently from study treatment) with at least 1 day of exposure in the year interval being reported; n, Number of patients who experienced at least one AE in this category
References
1. Cohen JA, et al. Ther Adv Neurol Disord. 2019;12:1756286419878324.
* Indication wording varies in different countries. The current website is a global information resource. Local Prescribing Information/ Summary of Product Characteristics approved by individual country’s regulatory authority is the primary source of information for the indication of fingolimod in the individual country.